NICE (UK) positive for Aquipta (atogepant) for treating migraine – AbbVie
NICE (UK): Atogepant can be used as an option for the acute treatment of migraine with or without aura in adults, only if, for previous migraines: i) at… read more.
NICE (UK): Atogepant can be used as an option for the acute treatment of migraine with or without aura in adults, only if, for previous migraines: i) at… read more.
Camurus announced that the FDA has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with… read more.
Pfizer Inc. announced the FDA approved Ibrance (palbociclib) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone… read more.
The National Institute for Health and Care Excellence (NICE) has issued thirteen Technology Appraisal decisions in June 2026, delivering nine positive recommendations, one updated recommendation, and two terminations…. read more.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a further nineteen positive recommendations spanning oncology, neurology, infectious disease, dermatology, cardiovascular medicine, diabetes,… read more.
United Therapeutics Corporation announced that the FDA has granted premarket approval (PMA) of the LungFXTM device (LungFX) for use in centralized ex vivo lung perfusion (EVLP), a procedure… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine nerandomilast (Jascayd) to treat adults with a lung disease called Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)…. read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has approved a semaglutide injection (Wegovy) to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis… read more.
NICE(UK): Seladelpar can be used, within its marketing authorisation, as an option to treat primary biliary cholangitis, including associated pruritus, in adults. It can be used: i) with… read more.
Eisai Co., Ltd. announced that the United Kingdom’s (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) has accepted for evaluation a marketing authorization application (MAA) for its in-house-discovered… read more.
Viridian Therapeutics, Inc. announced that the FDA has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disease characterized by… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Imvanex,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.